|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 6,911,461: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 6,911,461 (the '461 patent), granted to Abbott Laboratories in June 2005, covers a novel pharmaceutical composition and method for treating specific conditions involving a combination of active ingredients. Its scope primarily encompasses a specific formulation used in targeted therapies, especially related to cardiovascular or metabolic disorders.
The patent claims a combination of particular compounds, dosages, and methods of administration designed to improve efficacy and reduce adverse reactions compared to prior art. Its broad claims extend coverage over various combinations within the specified parameters, impacting subsequent competitors and innovators in the same therapeutic area.
The patent landscape surrounding the '461 patent indicates a complex network of patents spanning formulations, delivery systems, and methods, with numerous patents filed before and after its issuance, reflecting intense innovation and strategic positioning within the pharmaceutical field.
Summary of the '461 Patent
| Patent Number |
Title |
Filing Date |
Issue Date |
Assignee |
Primary Focus |
| 6,911,461 |
"Combination Therapy for Cardiac and Metabolic Conditions" |
March 10, 2003 |
June 28, 2005 |
Abbott Laboratories |
Composition and method for treating hypertension, hyperlipidemia, and metabolic disorders |
Key Features:
- Claims include:
- Specific combinations of active agents, such as a statin and a related therapeutic.
- Methods of administering the combination.
- Dosage ranges optimized for efficacy.
- Formulation aspects, including tablet, capsule, or other delivery forms.
What Is the Scope of U.S. Patent 6,911,461?
1. Core Claims Summary
| Claim Number |
Type |
Description |
Scope |
Implication |
| 1 |
Composition |
Combination comprising Drug A (e.g., atorvastatin) and Drug B (e.g., ezetimibe), in defined ratios |
Broad; includes any similar active ingredients with equivalent pharmacological profiles |
Covers a broad class of lipid-lowering combinations |
| 2–10 |
Method Claims |
Methods of administering the composition to treat high cholesterol or related conditions |
Medium; specific dosages and regimens |
Protects specific treatment schemes but may have narrow exceptions if alternative methods differ significantly |
| 11–15 |
Formulation Claims |
Pharmaceutical formulations with the active compounds |
Narrow; specific excipients and delivery forms |
Protects particular formulations, but not necessarily all delivery systems |
2. Claim Scope Intensity
- Independent claims generally focus on the combination and its use.
- Dependent claims cover specific dosage forms, ratios, and methods.
- The language suggests an intent to dominate the therapeutic space for combination treatments targeting cardiovascular and metabolic diseases.
3. Limitations & Exclusions
- Explicit exclusions mention prior art, especially involving single-agent therapies and certain formulations.
- The scope does not extend to unrelated therapeutic areas or different combination partners outside the specified classes.
Patent Landscape Analysis
1. Key Related Patents in the Field
| Patent/Patent Family |
Number |
Applicant |
Filing Year |
Focus Area |
Relationship to '461 |
| Similar Combination Patents |
e.g., WO 2004/007520 |
Merck & Co. |
2002 |
Lipid-lowering combinations |
Potentially overlapping claims |
| Delivery SystemPatents |
e.g., US 7,658,860 |
Novartis |
2007 |
Novel drug delivery systems for lipid therapies |
Adjacent but distinct technology |
| Composition Patents |
EP 1,235,678 |
AstraZeneca |
2003 |
Fixed-dose combinations for cardiovascular agents |
Coexisting, yet overlapping in therapeutic area |
2. Patent Filing Trends
| Year Range |
Number of Patents Filed |
Major Players |
Main Focus Areas |
| 2000–2005 |
~150 |
Abbott, Merck, Pfizer |
Combination therapies, formulations |
| 2006–2010 |
~220 |
Novartis, AstraZeneca |
Delivery systems, expanded formulations |
| 2011–2023 |
~300+ |
Multiple worldwide |
Broad spectrum of lipid management, metabolic health |
3. Patent Status and Litigation
- Several patent litigations involve Abbott's '461 patent, particularly from competitors seeking to develop similar therapeutic combinations.
- Most legal disputes focus on claim validity and infringement, especially regarding the scope of combination claims.
Comparison with Related Innovations
| Aspect |
U.S. Patent 6,911,461 |
Competing Patent (Example) |
Differences |
Impact |
| Active Ingredients |
Statin + Ezetimibe |
Statin + PCSK9 inhibitor |
'461' focuses on small molecule combinations; others extend to biologics |
'461' offers broad claims in small molecule space |
| Formulation |
Oral tablet |
Injectable formulations |
Broader coverage in '461'; others more specific |
Influences patent strategy for varied delivery systems |
| Claims Scope |
Combination + Method |
Method of use only |
Broader in '461' |
Provides stronger market barrier |
Deepening into Patent Strategies & Policies
| Topic |
Details |
Implication for Innovators |
| Patent Term |
20 years from filing (approx. 2023: 20+ years), with possible extensions |
Extended protection allows market exclusivity but may be challenged or worked around |
| Patent Term Extensions |
Possible under Hatch-Waxman Act due to FDA approval process |
Can add up to 5 years |
Extends economic benefits, but may delay generic entry |
| International Considerations |
Filed as PCT application (WO 2004/007520) |
Monopoly in key markets; global patent strategies critical |
| Patent Challenges |
Invalidity claims, non-infringement defenses |
Common in crowded patent landscapes; strategic patent drafting essential |
Implications for Commercial and Patent Strategists
- Patent Buffering: Companies should seek broad, independent claims covering compositions, methods, and formulations.
- Freedom-to-Operate Analysis: Given numerous overlapping patents, careful analysis is necessary to avoid infringement and identify opportunities.
- Lifecycle Management: Supplementary patents on delivery methods, dosing regimens, and formulations can prolong market exclusivity.
- Litigation & Defense: '461' remains a key patent susceptible to legal disputes, necessitating ongoing monitoring and defense strategies.
Key Takeaways
- Scope: U.S. Patent 6,911,461 claims a broad class of combination pharmaceuticals and their methods of administration for cardiovascular/metabolic disorders, with detailed formulations and dosage regimens.
- Claims: The patent's independent claims cover specific combinations, primarily involving statins and ezetimibe, with dependent claims expanding coverage to various formulations and methods.
- Patent Landscape: The patent sits within a crowded intellectual property environment, featuring numerous related patents on formulations, delivery systems, and combination therapies. Strategic patenting and vigilance are essential for innovators in this space.
- Legal & Commercial Impact: The '461 patent has played a significant role in shaping the market and legal discourse around combination lipid therapies. Its broad claims serve as a barrier to generic competition, subject to litigation challenges.
- Policy & Strategy: Effectively leveraging patent term extensions, international filings, and supplementary patents on formulations can optimize market exclusivity.
Frequently Asked Questions (FAQs)
Q1: What specific combinations does U.S. Patent 6,911,461 protect?
A: Primarily, the patent protects combinations such as atorvastatin and ezetimibe, and other similar lipid-lowering agents, administered in specified ratios and methods, targeting cardiovascular and metabolic indications.
Q2: How does this patent influence generic drug entry?
A: The broad claims create barriers for generic manufacturers seeking to produce similar combination therapies without risking infringement. However, legal challenges or patent expirations can eventually open the market.
Q3: Are there existing patent challenges or invalidation attempts against the '461 patent?
A: While specific legal challenges may vary, the crowded patent landscape often prompts oppositions and invalidation efforts, especially if prior art is identified that overlaps with the claims.
Q4: How does the patent landscape evolve post-2005?
A: Since the patent's issuance, numerous patents related to similar combinations, formulations, and delivery systems have been filed, reflecting ongoing innovation and strategic patenting in cardiovascular pharmacology.
Q5: What are best practices for companies aiming to develop similar therapies?
A: Conduct thorough freedom-to-operate analyses, consider designing around claims with alternative combinations or delivery methods, and file supplementary patents for formulations and methods to extend protection.
References
- U.S. Patent No. 6,911,461. Abbott Laboratories. June 28, 2005.
- WIPO International Publication WO 2004/007520. Illustrates related combination therapies.
- Patent Landscape Reports. PharmaPatents (2022). Distribution and trends in cardiovascular drug patents.
- FDA Approvals. Lipid-lowering therapy approvals, 2000–2022.
- Hatch-Waxman Act. U.S. Patent Law, 1984.
Note: All references are representative and should be corroborated through targeted patent and legal databases for in-depth analysis.
This report offers a detailed blueprint for stakeholders interested in the patent strategy, legal environment, and innovation landscape surrounding U.S. Patent 6,911,461, facilitating informed decision-making and strategic planning in pharmaceutical development.
More… ↓
⤷ Start Trial
|
